Caspofungin, an echinocandin antifungal agent, is active against invasive Aspergillus and Candida infections. In a phase I study in healthy volunteers, mild transient increases in serum aminotransferases were observed with the concomitant administration of caspofungin and cyclosporin A (CsA). As a result, it is recommended that the concomitant use of the two drugs be limited to those settings with appropriate risk-benefit balance. We retrospectively assessed safety data in 14 patients with refractory invasive mycoses who were treated concomitantly with CsA and caspofungin before the drug was licensed in Spain. In all, 13 patients were adults (median age, 31.5 years; range, 14-67 years). The average duration of concomitant therapy was 15 days (range, 2-43 days). No clinically significant elevations of serum aminotransferases were observed, and no patient had concomitant therapy discontinued or interrupted due to a drug-related adverse event. In this study of a limited number of patients, the coadministration of caspofungin and CsA was generally well tolerated.
aminotransferases
Caspofungin is the first member of the echinocandin class of antifungals, which acts through noncompetitive inhibition of beta-(1,3)-D-glucan synthase, leading to depletion of cell wall glucan, osmotic instability, and ultimately lysis of growing fungal cells. 1 A noncomparative study demonstrated a response rate of 45% among patients with acute invasive aspergillosis (IA) refractory to or intolerant of standard antifungals. 2 Moreover, the efficacy of caspofungin for the treatment of invasive candidiasis has been demonstrated in a large double-blind, amphotericin B (AmphB)-controlled randomized clinical trial. 3 Caspofungin appears to be generally well tolerated at doses between 35 and 70 mg daily. 4, 5 In a largely HIVinfected population of adults with mucosal candidiasis, the nature and frequency of caspofungin-related adverse experiences were similar to those seen with parenteral fluconazole. 5, 6 Comparable tolerability has been seen with longer courses of caspofungin in the treatment of IA and Candida infections. 2, 3, 5 Caspofungin also appears to have few significant drug interactions based on data from formal phase I studies and population pharmacokinetic analyses. 4, 7, 8 In two phase I studies conducted in healthy volunteers, caspofungin had no significant effect on cyclosporin A (CsA) pharmacokinetics, yet plasma concentrations of caspofungin were moderately elevated by the coadministration of CsA. 4, 5, 7, 8 Interestingly, five of 12 subjects given one or two doses of CsA while receiving caspofungin 70 mg daily experienced transient elevations of serum alanine aminotransferase (ALT) levels of p3-fold the upper limit of normal (ULN) within 48 h of the administration of CsA. Similar but smaller increases in serum aspartate aminotransferase (AST) concentrations were also seen. 4, 5, 7, 8 These results led to the exclusion of patients receiving CsA from the initial phase II/III clinical studies. Pending further data, it is recommended that the concomitant use of caspofungin and CsA be limited to those settings where the benefit to the patient outweighs the potential risk. 4 The present retrospective study was performed to examine the safety of the coadministration of caspofungin and CsA in transplant recipients.
Patients and methods

Patients
Between April 2001 and July 2002 (before marketing of caspofungin in Spain), 84 patients with documented fungal infections, who were refractory to or intolerant of standard antifungal therapy, received caspofungin as salvage therapy. All treatment courses were reviewed and approved by the Spanish Ministry of Health. Several months after completion of caspofungin therapy, all physicians responsible for those patients were contacted and asked to complete a survey for each treatment course. All cases were documented, with the exception of two patients whose medical records were no longer available for review. Those physicians who reported coadministration of caspofungin and CsA to their patients were asked to provide additional information, including extensive clinical and laboratory safety data (see below) based on the careful examination of the patients' clinical records. A total of 15 patients (17.9%) received at least 1 day of concomitant therapy with caspofungin and CsA. Another five patients had interrupted CsA prior to the onset of caspofungin, yet all of them discontinued CsA for reasons other than administering caspofungin. In 14 cases, caspofungin was instituted because of a refractory invasive fungal infection (IFI) and, in one patient, due to intolerance of standard antifungals. Diagnosis of IFI was modeled after the EORTC/MSG definitions. 9 Similarly, standard definitions and grading systems were used for acute 10 and chronic graft-versus-host disease (GVHD).
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Safety monitoring
The following data were taken into consideration: medical history with emphasis on prior and concurrent liver disease, diagnosis and treatment of underlying disease and IFI, type of transplant and follow-up, clinical signs and symptoms throughout treatment, laboratory data (AST, ALT, total and direct bilirubin, alkaline phosphatase, serum creatinine), CsA dosing and blood levels, other concomitant therapies, and cause of death and autopsy findings (if available). Changes in laboratory measurements were considered clinically significant if 420% with respect to baseline values (at the onset of concomitant CsA and caspofungin) and above the ULN.
Moreover, patients were retrospectively monitored for clinical and laboratory adverse reactions possibly, probably, or definitely related to caspofungin and/or CsA based on the treating physician's clinical judgment. For this purpose, standard definitions of adverse experiences were used. An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not determined to be related to that drug. An adverse experience was considered serious if life threatening or the consequence of an overdose, or when the event resulted in any of the following outcomes: death; permanent or substantial disability; new or prolonged hospitalization; cancer or a congenital anomaly; or a medical or surgical intervention to prevent one of the above-mentioned complications. Clinical adverse experiences were determined by the investigator. Results from periodic laboratory tests were reviewed by the investigators to determine if abnormal findings should be classified as laboratory adverse events.
When adverse experiences were identified, the investigator assessed the seriousness of the event and its causal relationship to the study drug. Investigators also recorded whether the adverse experience resulted in discontinuation of therapy. Any adverse experience judged even possibly related to the study drug was designated as 'drug related'. In those patients who died during or following caspofungin therapy, an assessment of causality was made to determine whether or not death was related to caspofungin. All suspected serious and unexpected caspofungin-related adverse reactions were immediately reported to the Spanish Medicines Agency after the information was received. Also, all suspected adverse reactions were registered in the pharmacovigilance database owned by Merck & Co., from which periodic safety update reports are generated. For the purpose of adverse reactions reporting only, the investigators were asked to assess the likelihood of a relationship between elevations in laboratory tests above the ULN not considered significant and the use of caspofungin.
Statistics
Consolidated laboratory data are expressed as median values and ranges. For the analysis of individual patients, liver function tests (LFTs) were plotted vs time. Regression analysis was used to detect series of LFT values that fit a simple linear trend before the onset of caspofungin, during concomitant administration of caspofungin and CsA, and after discontinuation of caspofungin. The nonparametric Wilcoxon's signed-rank sum test for matched series was used in the assessment of changes in LFTs and serum creatinine values at the onset and at the end of coadministration of caspofungin and CsA. Results were considered statistically significant if Po0.05.
Results
Patients characteristics
Of the 15 patients treated concomitantly with caspofungin and CsA, one could not be evaluated due to unavailability for review of most laboratory records during the study period. The remainder of this paper will focus on the 14 patients with available data. Patients' characteristics are summarized in Tables 1 and 2 . Within 1 year prior to the initiation of concomitant caspofungin and CsA, 10 patients had documented pre-existing liver disease ( Table 1 ). All patients were negative for hepatitis C virus serology. In total, 10 patients were IgG positive for one or more herpesviruses (CMV, VZV, HSV, EBV), yet none of them presented signs of active hepatitis of viral origin.
For allogeneic stem cell transplantation (SCT) patients, CsA was typically started at 5 mg/kg i.v., followed by 3 mg/ kg/day i.v. thereafter. In most institutions, dosing of CsA was generally adjusted to maintain trough blood levels within a range of 200-400 ng/ml. At onset of caspofungin, all patients were being treated with i.v. CsA, except one patient who was already receiving oral CsA (soft gelatin capsules); however, this patient was switched to i.v. CsA on the 7th day of caspofungin therapy. Two other patients switched from i.v. to oral CsA (one each of soft gelatin capsules and oral solution) on the 11th and 16th days of caspofungin therapy, respectively.
Caspofungin was always given to the patients as therapy for an IFI (Table 2 ). In all, 12 patients acquired the IFI during an episode of severe neutropenia; four of them remained neutropenic while on caspofungin therapy. All refractory patients had progressed on at least one i.v. formulation of AmphB (median total dose, 2910 mg; range, 320-12 000). Three of them had also received itraconazole with no response. One patient developed severe intolerance of AmphB and had experienced liver toxicity during a previous treatment course with itraconazole. Overall, the median duration of antifungal treatment prior to the onset of caspofungin was 17 days, ranging from 3 to 39 days, with four patients presenting with elevations of serum creatinine while receiving AmphB, two patients with other general intolerance of AmphB, and one patient with hepatitis.
Salvage caspofungin therapy typically consisted of a loading 70 mg dose followed by 50 mg daily thereafter. One patient received 35 mg daily after a loading dose of 70 mg on day 1 based on pharmacokinetic data, suggesting that CsA causes a moderate increase of caspofungin plasma concentrations. 8 Of the 14 patients, 11 received caspofungin in association with other systemic antifungals ( Table 2 ). The median duration of caspofungin treatment was 15 days (range, 4-43 days), with 12 patients receiving X10 days of treatment. Most of caspofungin therapy occurred in combination with CsA, as evidenced by a median duration of concomitant treatment of 15 days (range, 2-43 days).
In addition, all patients were concomitantly treated with multiple medications that may cause damage to the liver (according to the corresponding Summaries of Product Characteristics), including antimicrobials, immunosuppressors, diuretics, cytokines, and acid-suppressive drugs. Eight patients also received parenteral nutrition.
Trends in LFTs
Of 14 patients, 13 (92.9%) had one or more LFTs altered right before the onset of caspofungin. The most frequently altered parameter was ALT (10 patients), followed by total bilirubin and alkaline phosphatase (nine patients each), and AST (three patients). Overall, most of these alterations were attributed to nonspecific toxicity; nonetheless, in some patients specific causes of liver malfunction were identified: active acute GVHD (three cases), chronic GVHD (two cases), veno-occlusive disease (VOD), CsA therapy, and IFI involvement of the liver (one case each). In general, elevations of AST and ALT levels were of p3-fold the ULN. Two patients presented with elevations 43-fold the ULN: Patient 3 had ALT and AST levels of 1022 and 293 IU/l, respectively, which were attributed to acute GVHD grade IV, and; Patient 13 had an ALT level of 128 IU/l at the onset of caspofungin therapy due to reactivated extensive chronic GVHD. Another three subjects (Patients 1, 11, and 14) had experienced major elevations of ALT and/or AST within the previous 30 days due to acute GVHD, yet values had come down to p3-fold the ULN by the time caspofungin was started.
During concomitant therapy with caspofungin and CsA, 10 patients presented elevations of ALT and/or AST above the ULN; specifically, ALT alone became elevated in one patient, AST in six patients, and both in three patients. However, none of the patients discontinued the B30 IU/l) on the 13th day of caspofungin treatment, which, despite not being clinically significant (o20% increase from baseline), was judged by the investigator related to caspofungin; by the end of caspofungin therapy, AST was 14 IU/l and ALT levels, which were elevated at the onset of caspofungin, had shown a continuously declining trend (Figure 1) . None of the observed elevations of ALT and/or AST in the remaining nine patients were considered to be related to either caspofungin alone or the coadministration of caspofungin and CsA (Table 3) .
In an attempt to analyze systematically the overall impact of the coadministration of caspofungin and CsA on LFTs, we performed a matched nonparametric test comparing baseline and final values of the different parameters monitored throughout the study period for all 14 patients (Table 2) . While ALT levels were found to decline throughout the concomitant use of caspofungin and CsA (from a median baseline value of 66.5 IU/l to a median Regression analysis was used to detect either declining or increasing linear trends for AST and ALT before the onset of caspofungin therapy (diamonds), during concomitant administration of caspofungin and CsA (squares), and after discontinuation of caspofungin (triangles). The solid line indicates the upper limit of normality for the parameter tested. Dotted lines indicate the onset and end of caspofungin therapy. GVHD=Graft-versus-host disease.
Safety of caspofungin and cyclosporin A C Sanz-Rodriguez et al Table 3 Increments in ALT and AST levels judged unrelated to caspofungin SCT-related toxicity final value of 42.5 IU/l; P ¼ 0.006), no significant changes in AST, alkaline phosphatase, or total bilirubin were detected.
Other clinical and laboratory adverse events
Overall, side effects attributed to caspofungin therapy were seen in three patients (21.4%). None of the observed caspofungin-related adverse events led to discontinuation of caspofungin therapy by the patients' treating physicians. Patient 2 had an isolated determination of AST of 35 IU/l judged by the investigator related to caspofungin (see above). Total bilirubin also experienced transient increments up to 4.6 mg/dl on top of baseline 2.5 mg/dl, which were considered caspofungin related; however, a few days before the onset of caspofungin therapy, total bilirubin levels reached a maximum value of 7.4 mg/dl, which was then attributed to CsA toxicity. Patient 6 developed caspofungin-related nausea and vomiting, which was judged nonserious since the patient did not require premedication at any time during caspofungin therapy. Finally, Patient 9 developed caspofungin-related infusion reactions consisting of fever, shivering, and chills, and low serum potassium, which were both judged nonserious. Prior to caspofungin therapy, the patient had developed severe hyperbilirubinemia (up to 16.8 mg/dl of total bilirubin) and jaundice, which was attributed to toxicity caused by cyclophosphamide and CsA. During the following 4-day-long caspofungin therapy course, total bilirubin levels continued to increase up to 34.8 mg/dl; this latter increment was judged serious and caspofungin-related by the patient's treating physicians.
Side effects likely to be associated with CsA were: altered LFTs ( While on caspofungin therapy, five individuals (Patients 4, 5, 9, 10, and 13), who were all treated concomitantly with liposomal AmphB, experienced clinically significant elevations of serum creatinine (420% increase from baseline and above ULN). None of these five episodes was judged to be associated with the use of caspofungin. A matched nonparametric test was performed to compare baseline and final values of serum creatinine. Patient 4 was excluded from this analysis, since the diagnosis of progressive VOD was clearly responsible for the observed kidney dysfunction. The median baseline serum creatinine level was 1.1 mg/dl, ranging from 0.68 to 2.0, and the final value 1.3 mg/dl, ranging from 0.44 to 2.1 (P ¼ 0.09). The ULN for serum creatinine varied among different institutions, ranging from 0.9 to 1.6 mg/dl.
As expected, caspofungin had no significant effect on CsA pharmacokinetics in this study. Changes in CsA blood levels most likely reflected the typical fluctuations in transplant patients being managed for GVHD. Moreover, all investigators agreed that, in their limited experience, they had no additional difficulties in handling CsA blood levels while their patients were being treated with caspofungin.
Discussion
Caspofungin has few significant drug interactions as it is neither a substrate nor an inhibitor of the cytochrome P450 system. 1, 7, 8 Mild increases in serum aminotransferase levels were reported to have occurred in some healthy volunteers administered one or two doses of CsA while receiving caspofungin. 4, 5, 7, 8 Similar findings have been reported for other investigational echinocandins in multiple dose drug interaction studies. Two of 12 healthy volunteers experienced mild reversible elevations of hepatic aminotransferases while receiving 100 mg daily of anidulafungin and CsA oral solution at 1.25 mg/kg b.i.d. 12 Similarly, five out of 27 healthy adults experienced small and transient increases in ALT when exposed to concomitant micafungin and CsA. 13 The underlying mechanism for this interaction is currently unknown. CsA does not seem to affect the metabolism of neither micafungin nor anidulafungin by human microsomal fractions. 14, 15 The echinocandins appear to have no significant effects on CsA pharmacokinetics. 7, 8, 13 However, CsA may increase the area-under-the-curve of echinocandin antifungals. 7, 8, 12, 13 With caspofungin, the shape of the plasma profile obtained with coadministration of CsA suggests that the calcineurin inhibitor may have a reversible inhibitory effect on the echinocandin disposition. 7, 8 The caspofungin disposition process inhibited by CsA is unlikely to be a metabolic process, since the effect is evident rapidly after coadministration. A rat model of the drug interaction was developed, which demonstrated that caspofungin in the liver was reduced by coadministration of CsA, yet liver tissue binding of caspofungin appeared to be unaffected by CsA. These findings suggest that CsA inhibits the uptake of caspofungin into hepatocytes. 7, 8 However, it does not explain the elevation of liver aminotransferases noted to occur with echinocandins in combination with CsA.
In the absence of more definitive data on the underlying mechanisms and the clinical relevance of this interaction, the recommendation was made that the concomitant use of caspofungin and CsA be limited to those settings where the benefit to the patient outweighs the potential risk. 4 We have herein analyzed data on 14 patients who received concomitant CsA and caspofungin for varying periods of time. No clinically significant elevations of serum aminotransferases were observed; only in one patient an isolated elevation of AST levels up to 35 IU/l on the 13th day of concomitant therapy was judged by the investigator related to caspofungin. Nonetheless, the lack of a control comparative group to evaluate the frequency of LFT abnormalities in the absence of concomitant caspofungin and CsA, the reduced number of patients analyzed, and the subjective nature of determining adverse event causation, may certainly limit conclusions drawn from this study.
So far, limited data from patients with IFI treated concomitantly with caspofungin and CsA have become available. Trenschel et al 16 have reported their experience with 16 allogeneic SCT recipients treated with caspofungin as salvage therapy. Eight patients interrupted CsA prior to the onset of caspofungin therapy; yet, CsA was restarted in seven of them while receiving caspofungin. In addition, CsA was given without interruption in another seven patients during caspofungin therapy. No major acute side effects were noted. The mean serum ALT level was 8.5 IU/l at the onset of concomitant therapy and 22.4 IU/l by the end of it. 16 Kartsonis et al 17 have also communicated data on six patients who received concomitant CsA and caspofungin as participants in Merck-sponsored caspofungin clinical trials. The patients were all adults with a mean age of 48 years. Five had undergone allogeneic SCT and one had received a kidney transplant. All had IA and were refractory to at least one other antifungal agent. Patients received concomitant therapy with caspofungin and CsA for 2-56 days. Five patients were receiving CsA prior to the onset of caspofungin therapy and one patient was started on CsA while receiving caspofungin. Based on pharmacokinetic data, patients received a 70-mg loading dose of caspofungin followed by 35 mg daily (instead of 50 mg) thereafter. During the study period, none of the patients had clinically relevant elevations in serum aminotransferases on caspofungin plus CsA therapy, and no patient had concomitant therapy discontinued or interrupted due to a drug-related adverse event. 17 More recently, Marr et al 18 have reported preliminary data from a retrospective study in 40 allogeneic SCT and solid organ transplant recipients treated concomitantly with caspofungin and CsA. As expected in this population, LFT abnormalities were common and often considered due to GVHD, sepsis, other medical conditions, or other medications. Five (13%) patients had an elevation in AST, and none had an elevation in ALT, considered at least possibly related to coadministration of caspofungin and CsA. Two patients discontinued therapy due to laboratory hepatotoxicity related to multiple causes including the concomitant use of the two drugs. Nonetheless, Marr et al 18 concluded that there were no significant hepatic adverse events in this cohort of patients receiving caspofungin concomitantly with CsA.
Taken together, these data on the interaction between caspofungin and CsA, obtained from patients treated in a setting with appropriate risk benefit, are encouraging. Further evaluation of concomitant therapy with caspofungin and CsA in larger numbers of patients is warranted.
